|
HACE1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88737914186277E-15 |
| Normal-vs-Stage2 |
2.37609999453881E-08 |
| Normal-vs-Stage3 |
2.1538326677728E-14 |
| Normal-vs-Stage4 |
3.27050053705591E-10 |
| Stage1-vs-Stage2 |
8.883400E-01 |
| Stage1-vs-Stage3 |
1.461590E-01 |
| Stage1-vs-Stage4 |
5.016000E-01 |
| Stage2-vs-Stage3 |
4.067800E-01 |
| Stage2-vs-Stage4 |
6.897400E-01 |
| Stage3-vs-Stage4 |
6.853200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.37300000000196E-06 |
| Normal-vs-Asian |
1.47249999971066E-07 |
| Caucasian-vs-AfricanAmerican |
6.114200E-01 |
| Caucasian-vs-Asian |
1.996220E-01 |
| AfricanAmerican-vs-Asian |
6.827200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.4432899320127E-15 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
2.431000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.76358927461706E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.07950315353378E-11 |
| Normal-vs-Age(81-100Yrs) |
3.084600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.930770E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.250400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.728000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.740800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.557800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.077400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.644240E-01 |
| Classical-VS-Follicular |
7.503700E-02 |
| Classical-VS-Other |
9.140000E-01 |
| Classical-VS-Normal |
1.85759996274015E-09 |
| Tall-VS-Follicular |
8.410600E-01 |
| Tall-VS-Other |
5.518000E-01 |
| Tall-VS-Normal |
3.98749999686032E-09 |
| Follicular-VS-Other |
6.486200E-01 |
| Follicular-VS-Normal |
5.9064975133083E-12 |
| Other-VS-Normal |
8.678300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4432899320127E-15 |
| Normal-vs-N1 |
2.37920017021054E-10 |
| N0-vs-N1 |
8.541000E-01 |
|
|
